Evidence map›Paper›PMID 35507584›Full record

ArticlePloS one2022

Efficient gene transfection to lung cancer cells via Folate-PEI-Sorbitol gene transporter.

Kye Soo Cho, Sanghwa Kim, Hyung Bin Chun, Jae Hee Cheon, Myung-Haing Cho, Ah Young Lee, Rohidas B Arote

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Kye Soo ChoDepartment of Tumor Immunology, National Cancer Center, Goyang, Republic of Korea.ORCID 0000-0001-9137-0725
Sanghwa KimLaboratory of Toxicology, Research Institute for Veterinary Science and College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea.
Hyung Bin ChunDepartment of Life Science, Waterloo University, Waterloo, Ontario, Canada.ORCID 0000-0001-7186-6387
Jae Hee CheonDepartment of Internal Medicine, Yonsei University College of Medical Science, Seoul, Republic of Korea.
Myung-Haing ChoRNABIO, Seongnam, Gyeonggi-do, Republic of Korea.
Ah Young LeeDepartment of Life Science, Waterloo University, Waterloo, Ontario, Canada.ORCID 0000-0002-8776-0920
Rohidas B AroteDepartment of Molecular Genetics & Dental Research Institute, School of Dentistry, Seoul National University, Seoul, Republic of Korea.ORCID 0000-0001-5215-2522
Seoul National University · KRUniversity of Waterloo · CAYonsei University · KRKoreaBio · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is known to be one of the fatal diseases in the world and is experiencing treatment difficulties. Many treatments have been discovered and implemented, but death rate of patients with lung cancer continues to remain high. Current treatments for cancer such as chemotherapy, immunotherapy, and radiotherapy have shown considerable results, yet they are accompanied by side effects. One effective method for reducing the cytotoxicity of these treatments is via the use of a nanoparticle-mediated siRNA delivery strategy with selective silencing effects and non-viral vectors. In this study, a folate (FA) moiety ligand-conjugated poly(sorbitol-co-PEI)-based gene transporter was designed by combining low-molecular weight polyethyleneimine (LMW PEI) and D-sorbitol with FA to form FPS. Since folate receptors are commonly overexpressed in various cancer cells, folate-conjugated nanoparticles may be more effectively delivered to selective cancer cells. Additionally, siOPA1 was used to induce apoptosis through mitochondrial fusion. The OPA1 protein stability level is important for maintaining normal mitochondrial cristae structure and function, conserving the inner membrane structure, and protecting cells from apoptosis. Consequently, when FPS/siOPA1 was used for lung cancer in-vitro and in-vivo, it improved cell viability and cellular uptake.

Indexed as

Lung NeoplasmsSorbitolCell Line, TumorFolic AcidHumansPolyethyleneimineRNA, Small InterferingTransfectionFolic AcidPolyethyleneimineRNA, Small InterferingSorbitol

Identifiers

PMID35507584
PMCPMC9067668
OpenAlexW4229048491

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.